News

June 24, 2024 – AstriVax enters clinical phase with its novel vaccine platform technology
March 18, 2024 – AstriVax Rounds Out ExecutiveTeam with Chief Business Officer(CBO) Dr. Gregory Fanning
December 12, 2023 – AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccineastrivax-awarded-3-million-grant-to-advance
October 10, 2023 – AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag
August 22, 2023 – Dr. Christian Brander and Dr. Mala Maini Join World-class Scientific Advisory Board of AstriVax
May 30, 2023 – AstriVax Awarded €2.5 Million Grant to Advance Innovative Vaccine Platform
March 24, 2023 – AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development
February 27, 2023 – Happy readings on this article in Vaccine Insights, based on an interview with two of the AstriVax co-founders Kai Dallmeier and Hanne Callewaert, describing the advantages of the Plasmid Launching Live Attenuated Virus (PLLAV) technology that is being further developed at AstriVax. Published by Charlotte Barker, editor in Vaccine Insights.
Read the testimonial of AstriVax CEO Hanne Callewaert in the BVA | Belgian Venture Capital & Private Equity Association
November 30, 2022 – Nice article on AstriVax in ‘De Tijd’ with our CEO Hanne Callewaert and PMV. Thank you Bart De Taeye and Filip Goossens from PMV to highlight the importance of a strong team as necessary ingredient for a successful start-up.
November, 2022 – AstriVax receives the European Lifestar Award for ‘Seed-Stage Finance Raise of the Year 2022’ by LSX – partnering for Life Science eXecutives
AstriVax receives the “Best Pitch Award” at Immunity for Health from Flanders Vaccine, sponsored by the Biotech Innovation Procurement Platform (BIPP)
September 26, 2022 – AstriVax: thermostable, plug-and-play vaccines using plasmids – Biocentury
September 26, 2022 – Dr. Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax
Leuvense vaccinstart-up tankt record van 30 miljoen euro
August 25, 2022 – KU Leuven spin-off AstriVax raises €30 million to build vaccine platform
August 25, 2022 – Spin-off KU Leuven haalt 30 miljoen euro op voor ontwikkeling vaccins

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News

News

All Publications